H.C. Wainwright analyst Joseph Pantginis believes upcoming catalysts warrant owning shares of Fibrocell Science. The analyst believes the May 19 data readout for FCX-007 will "represent the beginning of the tipping point for the shares." The readout should catalyze upcoming discussions with the FDA, resulting in what should be a "quick shift" to a pivotal program for the ongoing significant unmet medical need in recessive dystrophic epidermolysis bullosa, Pantginis tells investors in a research note. He reiterates a Buy rating on Fibrocell with a $6 price target.